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Abstract
Although doxorubicin (DOX) is a very effective antineoplastic agent, its clinical use is limited by a dose-dependent,
persistent and cumulative cardiotoxicity, whose mechanism remains to be elucidated. Previous works in animal models
have failed to use a multi-organ approach to demonstrate that DOX-associated toxicity is selective to the cardiac tissue. In
this context, the present work aims to investigate in vivo DOX cardiac, hepatic and renal toxicity in the same animal model,
with special relevance on alterations of mitochondrial bioenergetics. To this end, male Wistar rats were sub-chronically
(7 wks, 2 mg/Kg) or acutely (20 mg/Kg) treated with DOX and sacrificed one week or 24 hours after the last injection,
respectively. Alterations of mitochondrial bioenergetics showed treatment-dependent differences between tissues. No
alterations were observed for cardiac mitochondria in the acute model but decreased ADP-stimulated respiration was
detected in the sub-chronic treatment. In the acute treatment model, ADP-stimulated respiration was increased in liver and
decreased in kidney mitochondria. Aconitase activity, a marker of oxidative stress, was decreased in renal mitochondria in
the acute and in heart in the sub-chronic model. Interestingly, alterations of cardiac mitochondrial bioenergetics co-existed
with an absence of echocardiograph, histopathological or ultra-structural alterations. Besides, no plasma markers of cardiac
injury were found in any of the time points studied. The results confirm that alterations of mitochondrial function, which are
more evident in the heart, are an early marker of DOX-induced toxicity, existing even in the absence of cardiac functional
alterations.
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Introduction
Doxorubicin (DOX) is an anthracycline antibiotic drug which
has been effectively and widely used in the clinic to treat several
types of human and non-human cancers [1]. However, adverse
side effects can be observed during or after treatment cessation,
with a dose dependent and cumulative cardiotoxicity being the
most complex and difficult to manage event [1,2]. In fact, the
associated risk of developing congestive heart failure was one of the
main reasons that lead to limitation of the maximum allowed
dosage during DOX treatment [3].
Acute cardiac toxicity occurs early during the treatment and
usually includes myopericardits, sinus tachycardia, reversible
arrhythmias, prolonged QT interval and flattening of the T wave,
being easily manageable and disappearing once the treatment is
ceased [2]. Alternatively, patients may develop chronic cardiotox-
icity which can appear right after the end of the treatment or even
years later [2,4]. Unlike acute toxicity, the dose-dependence
together with its difficult early detection makes chronic toxicity a
life-threatening and largely uncontrolled condition.
The mechanisms underlying DOX-selective cardiotoxicity have
been the focus of interest in the last four decades, but there is
hardly any consensual conclusion. Nevertheless, it is accepted that
DOX antitumor activity is completely independent from cardiac
toxicity, which may involve disruption of mitochondrial function
[2,5]. Distinctive features of DOX-induced mitochondrial dys-
function in the cardiac tissue include inhibition of oxidative
phosphorylation, decreased calcium-loading capacity and in-
creased reactive oxygen species (ROS) production [2,5,6].
Despite the fact that DOX toxicity has been described as being
cardiac selective, none of the hypotheses proposed to date [2] fully
explains the pronounced cardiac effects when compared with
other vital tissues. Although several animal models have been
generated to investigate either sub-chronic [7,8,9,10,11] or acute
[12,13,14] DOX toxicity, one limitation of the majority of studies
is that only one organ was investigated. Thus, comparing DOX
multi-organ effects from different reports becomes non-accurate,
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strain, age and treatment protocols differ from publication to
publication. By searching PubMed for reports using the keywords
‘‘mitochondria’’ and ‘‘doxorubicin’’ and narrowing the search to
works performed in animal models and in three distinct tissues
(heart, liver and kidney, Table S1), only 16 hits were obtained (Fig.
S1). These studies investigated DOX toxicity in the three tissues
harvested from the same experimental protocol. However, except
for two relatively recent works, most reports originated in the 80 s
and did not compare mitochondrial dysfunction with pathophys-
iological state, genetics, metabolomics or proteomics, which we
believe are critical to better understand DOX-induced tissue
toxicity. In an attempt to increase the knowledge regarding DOX-
induced selective cardiotoxicity, the objective of the present work
was to measure alterations of mitochondrial bioenergetics in the
heart, liver and kidney after two distinct treatment protocols (acute
vs. sub-chronic) in male Wistar rats. Mitochondrial function end-
points were associated with tissue histological alterations (all three
tissues) and function (heart). Our hypothesis is that alterations of
mitochondrial bioenergetics occur predominantly in the heart and
are an early and sensitive marker of DOX-induced toxicity,
occurring even in the absence of histological alterations. A second
tandem hypothesis is that cardiac mitochondrial toxicity is
detectable only in the sub-chronic treatment.
The two distinct treatment protocols used in the present work
were already reported in the literature [13,15] and are accepted
models to investigate DOX-mitochondrionopathy. Note that
accordingly to a reported equation [14], the actual total dosages
of our treatment protocols are slightly below the maximum dosage
allowed in human chemotherapy [16], as our objective was not to
induce substantial tissue damage but to mimic biochemical and
functional alterations that are usually observed in DOX-treated
patients.
Materials and Methods
Reagents
DOX hydrochloride, (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hy-
droxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyace-
tyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione hydrochlo-
ride, chemical purity $98%, was obtained from Sigma-Aldrich
Quimica SA (Sintra, Portugal) and prepared in a sterile saline
solution, NaCl 0.9% (pH 3.0, HCl) and stored at 4uC for no
longer than five days upon rehydration. All other chemicals were
of the highest grade of purity commercially available. Aqueous
solutions were prepared in ultrapure (type I) water (Milli-Q Biocel
A10 with pre-treatment via Elix 5, Millipore, Billerica, MA, USA).
For non-aqueous solutions, ethanol (99.5%, Sigma-Aldrich
Quimica SA, Sintra, Portugal) was used as solvent.
Animal Care
Animal handling was performed in accordance with the
European Convention for the Protection of Vertebrate Animals
used for Experimental and Other Scientific Purposes (CETS
no.123) and Portuguese rules (DL 129/92). The procedures were
approved by the CNC Committee for Animal Welfare and
Protection. Animal handlers and the authors GCP, SPP and PJO
are credited by the European Federation for Laboratory Animal
Research (FELASA) category C for animal experimentation
(accreditation no. 020/08). Fourteen weeks of age (acute protocol)
or 6 weeks of age (sub-chronic protocol) male Wistar rats,
Crl:WI(Han), were purchased from Charles River (France),
acclimated for 10–14 days prior to the initiation of experiments
and maintained in the local animal house facility (CNC – School
of Medicine, University of Coimbra, Coimbra, Portugal). Animals
were group-housed in type III-H cages (Tecniplast, Italy) with
irradiated corn cob grit bedding (Scobis Due, Mucedola, Italy) and
environmental enrichment and under controlled environmental
requirements (22uC, 45–65% humidity, 15–20 air changes/hour,
12 h artificial light/dark cycle, noise level ,55 dB) and free access
to standard rodent food (4RF21 GLP certificate, Mucedola, Italy)
and ad libitum acidified water (at pH 2.6 with HCl).
Experimental Design
For the acute study, the experimental protocol was initiated
with 16 weeks old rats (N=34), randomly allocated in pairs and
administered with either DOX (20 mg Kg
21 of body weight, i.p.,
n=17) or with an equivalent volume of vehicle solution (NaCl
0.9%, i.p., n=17) exactly 24 hours before sacrifice, as previously
described [13].
For the sub-chronic study, the experimental protocol was
performed with 8 weeks old rats (n=40) randomly grouped in
pairs and weekly injected with a subcutaneous injection in the
scruff or flank of either DOX (2 mg kg
21, n=20) or equivalent
volume of vehicle solution (NaCl 0.9%, s.c., n=20) during seven
weeks, and sacrificed one week after the last injection, as
previously described [15].
All animals were injected during the light phase of the cycle,
observed daily and weighed at the beginning and at the end of the
experimental treatment period, being also weekly weighed at the
time of injection. Animals were euthanized in pairs by cervical
dislocation followed by decapitation, to confirm death and
exsanguination. Blood was collected for further biochemical
analysis. Rats were sacrificed between 9:00 and 10:00 AM to
eliminate possible effects due to diurnal variation and were not
fasted before sacrifice. Organs were immediately extracted from
the body and quickly washed in appropriate buffer before being
weighed.
Blood Analysis
Blood was collected after decapitation to sterile tubes without
additives. After blood clot formation, serum was separated by
centrifugation at 1,6006g during 10 minutes at 4uC (Sigma 3–
16 K, 1333 rotor). The supernatant was then transferred to
microtubes and centrifuged at 16,0006g, 20 minutes at 4uC
(Eppendorf 5415 R, FL062 rotor). Serum samples were main-
tained for a short time at 4uC for analysis by an external certified
laboratory, or stored frozen at 280uC for troponin I (TnI)
analysis. The latter was performed by external trained personal
one month after collection using the singleplex Rat Cardiovascular
Panel (RCVD1-89K, Millipore, Arium, Portugal). Blood analyses
were performed by blinded operator.
Histological Analysis
Organs were immersion-fixed in Bouin’s solution for 24 h and
then washed with 70% alcohol until the solution became clear and
stored in 70% alcohol until the histological analysis was
performed. At that time, after several incubations with increasing
alcohol percentages (70%, 90%, and 100%) and xylol, tissues were
processed using a normal paraffin procedure and sectioned (3 mm
thick). The sections were then de-paraffinized with xylol and
incubated with solutions containing decreasing alcohol content
(100% and 95%). All slides were stained with hematoxilin and
eosin (HE) by using standard procedures. The samples were
covered with coverslips in Eukitt mounting medium and then
visualized in a Nikon Eclipse 80I microscope coupled with a
camera and computer. Morphological assessment was conducted
in a ‘‘blind’’ fashion by a certified professional.
Mitochondrial Doxorubicin Toxicity in Wistar Rats
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After organ harvesting and washing, a small slice (2–5 mm) was
cut and fixed in 3% glutaraldehyde in phosphate buffer
(100 mM NaH2PO4, pH 7.3), postfixed in 1% osmium tetroxide
in same buffer and dehydrated in solutions containing increasing
alcohol percentages (70%, 90%, and 100%) before being
embedded in Spurr’s resin. Ultrathin sections were obtained with
an LKB ultra-microtome Ultrotome III (GE Healthcare, Little
Chalfont, Buckinghamshire, UK), stained with methanolic uranyl
acetate followed by lead citrate, and examined with a JEOL Jem-
100SX electron microscope (JEOL, Tokyo, Japan) operated at
80 kV. The operator was blinded to treatment groups and took 5
to 10 micrographs of random fields.
Echocardiogram
Echocardiograms were performed under the same specifications
as previously described [17]. Five days after the last injection, sub-
chronically-treated animals, free of anesthesia, were examined
lying in the left lateral decubitus position and using a commercial
available echocardiograph system (VIVID i, G.E. Helthcare),
equipped with an 11.5 MHz transducer. Every parameter was
measured accordingly to the American Society for Echocardiog-
raphy guidelines (www.asecho.org/guidelines/) and results were
directly obtained from the equipment software by a cardiologist
blinded for treatment groups. Left ventricular mass (LV mass) was
calculated using a standard cube formula which assumes a spherical
left ventricular geometry [18] according to the following equation:
LVmass~1:04|½(LVDdzLVPWzIVS)
3{LVDd3 . Results
are expressed in mg and 1.04 represents the specific gravity of
muscle. Only four animals of each group were analyzed due to
limitations in the time slot available for the cardiologist/apparatus
used.
Isolation of Mitochondrial Fractions
Mitochondria were isolated by the standard procedure usually
used in our laboratory [19,20,21]. Organs were excised and finely
minced in an ice-cold isolation medium containing 250 mM
sucrose, 10 mM HEPES, 1 mM EGTA and 0.1% defatted BSA
(pH 7.4, KOH). For the isolation of cardiac mitochondrial
fractions, the isolation medium was supplemented with 0.5 mg/
mL of protease (Subtilisin A, Type VIII from Bacillus licheniformis,
Sigma-Aldrich). The mitochondrial protein after isolation was
quantified by the biuret method using bovine serum albumin as a
standard [22] and mitochondrial preparation was kept on ice
during experiments, which were carried out after a 20 min
recovery and within 5 hours post-isolation.
Oxygen Consumption
Oxygen consumption of isolated mitochondria was monitored
polarographically with a Clark oxygen electrode connected to a
Kipp and Zonen recorder in a 1 mL thermostatic, water-jacketed
open chamber with magnetic stirring at 30uC, simultaneously with
mitochondrial membrane potential measurements (see 2.10). The
standard respiratory medium consisted of 130 mM sucrose,
10 mM EGTA, 50 mM KCl, 5 mM H2PO4, 5 mM HEPES
(pH 7.3, KOH) and supplemented with 2.5 mM MgCl2 for liver
and kidney. Mitochondria were suspended at a concentration of
0.5 (heart) or 1.0 (liver and kidney) mg protein/mL in the
respiratory medium and mitochondrial state 2 respiration was
initiated with 5 mM glutamate plus malate (mitochondrial
energization through complex I) or 5 mM succinate in the
presence of 2 mM rotenone (mitochondrial energization through
complex II). Adenosine diphosphate (ADP) (225–250 nmol) was
added to initiate state 3 respiration. State 4 respiration was defined
as oxygen consumption after ADP consumption. The respiratory
control ratio (RCR) was calculated as the ratio between state 3
over state 4 and it is an indicator of oxidative phosphorylation
coupling and mitochondrial membrane integrity. ADP/O ratio,
which is expressed as the ratio between the amount of ADP added
and oxygen consumed during state 3 respiration, is an index of
oxidative phosphorylation efficiency. Respiration rates were
calculated considering that the saturation oxygen concentration
was 236 mMa t3 0 uC.
Mitochondrial Transmembrane Electric Potential
The mitochondrial transmembrane electric potential (DYmax)
was monitored by tetraphenylphosphonium ion (TPP
+) distribu-
tion (see 2.9), by using a TPP-selective electrode in combination
with a Ag/AgCl saturated reference electrode, as previously
described [21]. The difference in potential between the selective
TPP
+ electrode and the reference electrode was measured with a
potentiometer and continuously recorded in a Kipp and Zonen
recorder (model BD 121; Kipp & Zonen B.V., Delft, Netherlands).
Experimental conditions were the same as for oxygen consump-
tion assays with the inclusion of 3 mM TPP
+ in the reaction media.
Absolute DYmax values (mV) were determined from the equation
originally proposed by Kamo [23], assuming Nernst distribution of
the ion across the membrane electrode. No correction was made
for the ‘‘passive’’ binding of TPP
+ to mitochondrial membranes
because the purpose of the experiments was to show relative
changes in potential rather than absolute values. As a conse-
quence, some overestimation for the DYmax values may be
anticipated. A matrix volume of 1.1 mL/mg protein was assumed.
Aconitase Activity
Mitochondrial protein (200 mg) was diluted in 0.6 ml buffer
containing 50 mM Tris–HCl (pH 7.4) and 0.6 mM MnCl2 and
sonicated for 10–20 seconds, followed by centrifugation at
16,0006g for 5 minutes. Aconitase activity was immediately
spectrophotometrically measured (Jasco V-560, Jasco Europe,
Milan, Italy) by monitoring the formation of cis-aconitate from
isocitrate at 240 nm in 50 mM Tris-HCl (pH 7.4) containing
0.6 mM MnCl2 and 20 mM isocitrate at 25uC [24]. All assays
were performed in triplicate. Enzyme activity was calculated by
using the mean of the slopes of the three replicates, obtained
before the record reached a plateau. Results were expressed as
percentage of control, which was 174.0627.8 nmol mgprotein
21 -
min
21, 258.3632.4 nmol mgprotein
21 min
21 and
245.2631.1 nmol mgprotein
21 min
21 for heart, liver and kidney,
respectively, using e240=3.6 mM
21 cm
21 [24].
Statistical Analysis
All data was assessed for normality using the Kolmogorov-
Smirnov test with Dallal-Wilkinson-Lilliefor correction and for
equality of variances using the F test. Since group sample sizes are
equal and the parametric statistical tests applied in this work are
robust for moderate deviations from homoscedasticity [25],
parametric tests were still applied when homoscedasticity was
not observed. However, when data normality was rejected, a
squared-root, logarithmic or reciprocal transformation was applied
in an attempt to achieve normality. If data still rejected normality,
the correspondent non-parametric statistical test was used.
Nevertheless, data is presented to the reader in non-transformed
values for ease of comprehension. In the text, data is expressed as
percentage of the difference of means plus its standard error or as
percentage of the means difference plus its standard error for data
related to isolated mitochondrial fractions. In both situations, the
Mitochondrial Doxorubicin Toxicity in Wistar Rats
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experimental model. Statistical significance between means was
determined using two-tailed Student’s t test. When homoscedas-
ticity was not found, Welch’s correction was applied and in the
absence of normality, the Mann-Whitney test was used instead. To
exclude the random effect associated with daily mitochondrial
isolation and electrode variability, a matched pairs Student’s t test
or its non-parametric correspondent Wilcoxon matched pairs test
were performed. Differences were considered significant at 5%
level and p value was categorized accordingly to their interval of
confidence. Statistical analyses were performed using Graph Pad
Prism version 5.0 (GraphPad Software, Inc., San Diego, CA,
USA).
Results
Animal and Organs Mass
Control and DOX-treated animals in the acute model did not
show alterations in their body mass in the 24 hours subsequent to
DOX administration (Table 1). However, when animals were
individually analyzed, i.e. when the mean of the arithmetic
difference between initial and final body mass of every individual
was calculated for the first 24 h, the control group showed a body
mass variation of 20.3561.02 g (n=17) while variation in DOX-
treated group, 215.1 g 61.7 g (n=17) representing about 4% of
total body mass, was significantly lower (p,0.001). Surprisingly, a
decrease of 7.662.7% in heart mass was observed 24 h after the
single DOX injection but no alteration was observed in other
tissues analyzed (1.664.4% increase in liver and 3.163.9%
decrease for kidney, Table 1). Therefore, heart mass over body
mass ratio showed a significant decrease of 5.862.3% while no
changes were found for liver or kidney (3.662.6% increase and
1.463.6% decrease, respectively; Table 1).
Treatment of Wistar rats with seven weekly DOX injections
caused a significant reduction in body mass gain of animals, as
seen by the difference of body mass values between groups
(13.862.1%; Table 1). While the body mass variation of the
control group during the treatment showed an increase of
49.162.9%, the DOX-treated group only increased body mass
by 31.263.1%, which can be easily observed in the body mass
gain profile depicted in Fig. 1. However, it was interesting to
observe that the alteration in heart mass detected in the acute
model was not present in the sub-chronic protocol at the end of the
treatment period (Table 1). Since only a non-significant decrease
of all tissues (2.465.6%, 3.264.0% and 5.263.6% for heart, liver
and kidney, respectively) was observed, the ratio of organ mass to
body mass was increased in all analyzed tissues (13.766.6%,
12.463.5% and 10.064.1% for heart, liver and kidney, respec-
tively; Table 1). The results reflect a change in body mass rather
than alterations in tissue mass.
It should be noticed that although the objective of the
experimental protocol was to induce a sub-chronic response and
therefore a lower rate of mortality, one animal died during DOX
treatment (marked with an arrow, Fig. 1). This treated animal
received all seven DOX injections and died precisely one week
after the last. Nonetheless, the animal did not show any distinct
sign of distress or illness when compared with its counterparts. A
standard necropsy was performed in the deceased animal but no
particular abnormality was perceived, including heart hypertrophy
or ascites. Liver and kidney tissues appeared normal in size,
morphology and color. The only thing to point out was the fact
that this particular animal showed the larger decrease in weight.
Therefore, the mortality rate associated with the present study is
5% (1 out of 20).
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Despite the fact that lactate dehydrogenase (LDH), a general
marker for tissue damage, is not altered (21.8614.0%; Table 2) in
the acute model, the non-specific hepatic marker, aspartate
aminotransferase (AST), is markedly elevated 91.0617.2%. Serum
creatine kinase is unchanged (1.7616.0%) as well as markers of
renal function, namely urea, creatinine, uric acid or blood urea
nitrogen (BUN). The observed high levels of the hepatic-specific
marker, alanine aminotransferase (ALT), 141626%, together with
the lower AST to ALT ratio (15.367.5%) and total protein levels
(TP; 9.861.7%) suggest impaired liver function in DOX-treated
animals. Increased cardiac injury, as evaluated by measuring
troponin I (TnI) was not significantly increased in the acute model
(value increased 15611% vs. control). Regarding circulating-
blood lipids, triglycerides were decreased by 53613% 24 hours
after the acute treatment but no alteration was found in total
cholesterol (4.667%).
Notwithstanding, chronically-DOX-treated rats were hyperlip-
idemic with the treated group showing both an increase in
triglycerides and cholesterol (196640% and 127624%, respec-
tively; Table 2). TnI levels were also increased by 11612%,
although the difference was not statistically significant. Interest-
ingly, all other parameters analyzed were significantly decreased in
comparison to control animals (average of the parameters
variation of 17.3%, ranging from 8.7% to 31.4%), with the
exception of LDH, uric acid and transaminases ratio, which,
despite being also decreased in the DOX-treated group, did not
reach statistical significance when compared with the saline group.
Echocardiography
Animals from sub-chronic DOX treatment were submitted to
an echocardiogram 5 days after the 7
th injection in order to
evaluate cardiac morphology and function parameters. No
abnormality was found in the four animals analyzed (Table 3).
Thickness of the walls and left ventricular diameter, ejection
fraction and fraction shortening were not different from the
Figure 1. DOX decreases body mass gain over time in a sub-
chronic toxicity model. After the fourth injection, the body mass of
DOX-treated animals started to be distinctly different from the saline-
treated and therefore the growth profile is dramatically changed at the
end of treatment. Only one DOX-treated animal died during the
protocol (indicated by the black arrow). Animals in the control group
are depicted by open circles while DOX-treated animals are in full
circles. Lines represent the means of each group at each time point. S –
sacrifice time-point.
doi:10.1371/journal.pone.0038867.g001
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variation of 0.25%, ranging from 0.16 to 0.40%).
Histopathology and Ultrastructure Analyses
When analyzing at least three different samples from each tissue
and from each treatment protocol, no obvious sign of damage or
morphological alterations were found after histological analysis
(Fig. 2). Hearts from treated animals in both treatment protocols
did not present signs of fibrosis or any hallmarks of later stages of
DOX toxicity. However, in the representative pictures of cardiac
slices, minor cytoplasmic vacuolization in the acute model (Fig. 2,
Panels A and B) and also minor increase in cellular volume in the
sub-chronic model (Fig. 2, Panels C and D) can be observed.
Livers were morphologically normal; however, minor centrilobu-
lar dilation was observed, while hepatocytes showed citoplasmic
heterogeneity due to vacuolization. Nevertheless, the vacuolization
was more prominent in slices from the sub-chronic model (Fig. 2,
Panels E–H). When renal slices were observed with hematoxylin
eosin (HE) stain, no differences were found between control and
treated group regardless of the treatment protocol used (Fig. 2,
Panels I–L).
In terms of tissue ultrastructure, electron micrographs of cardiac
slices from acutely treated animals (Fig. 3, Panel B and D) showed
a cellular structure not dissimilar to control (Fig. 3, Panel A and
C). The myofibrillar disorganization, cytoplasm vacuolization and
swollen mitochondria usually observed after DOX treatment in
other rodent models [26,27] were not present in the acute
treatment model (Fig. 3, Panels A–D). In fact, myofibrillar Z-
bands were well defined and with narrow A-bands (Fig. 3, Panels
C and D). Likewise, kidney electron micrographs were similar to
control counterparts (Fig. 3, Panels H–K). However, hepatic slices
presented more heterogeneous cytoplasm with high numbers of
vacuoles and lipid-like droplets (Fig. 3, Panel E). Moreover, liver
mitochondria from DOX acute treated animals appear to be
preferentially in the condensed conformation (Fig. 3, Panel G)
rather than the orthodox one observed in control micrographs
(Fig. 3, Panels D and F).
Regarding the sub-chronic model (Fig. 3, Panels L-X), cardiac
samples from treated animals also showed normal sarcomeres with
well-defined Z-bands and organized myofibrils (Fig. 3, Panels A–
D). Nevertheless, the cytoplasm appeared to present more
vacuolization (Fig. 3, Panel M) although mitochondrial morphol-
ogy was not dissimilar from control micrographs (Fig. 3, Panels L
and N). In liver tissue, the striking evidence is the abundance of
small vacuoles in the cytoplasm of hepatocytes from sub-
chronically treated animals (Fig. 3, Panel S) and, although
mitochondria appear to be greater in volume in some images,
the overall observation is that they are not different in morphology
when compared with saline treatments (Fig. 3, Panels P and R).
Mitochondria from renal slices appear in an intermediate
conformation between orthodox and condensed forms (Fig. 3,
Panel X).
Mitochondrial Bioenergetics
Mitochondrial bioenergetics was evaluated in the three tissues to
detect distinctive DOX-induced alterations. State 3 respiration
mimics an increase in workload which is observed in vitro after
ADP-induced simulation. State 4 respiration is observed after all
ADP is phosphorylated, representing a steady-state of the
respiratory chain, controlled mostly by the passive and unspecific
diffusion of protons through the inner mitochondrial membrane.
Similarly, the phosphorylation lag phase represents the time
needed for the phosphorylative system to convert all added ADP
to ATP, i.e., the time elapsed to mitochondrial repolarization after
ADP depolarization.
In the acute model, complex I-sustained mitochondrial state 3
respiration was increased in hepatic, decreased in renal and not
altered in cardiac fractions (14.765.5%, 5.362.0% and
4.465.3%, respectively; Fig. 3). However, despite equal variation
patterns observed for the lag phase, ranging from 13 to 17%
between tissues, there was no statistical difference between groups
(Table 4). The previous detected differences for complex I-
sustained mitochondrial state 3 respiration were absent when
substrates for complex II were used (4.166.0%, 5.967.9% and
6.766.7% for heart, liver and kidney, respectively). State 4
respiration, RCR and ADP/O remained unchanged in all
fractions regardless of the respiration substrate used (Figs. 3 and
4). The same was observed for all other parameters related to
mitochondrial membrane potential.
Cardiac mitochondria from sub-chronic DOX-treated animals
presented decreased state 3 respiration when using both respira-
tory complexes (15.864.9% and 12.863.6% for complex I and II,
respectively; Fig. 3) and lower state 4 respiration, although only
statistically significant when substrates for complex II were used
(12.066.6% and 19.864.2% for complex I and complex II,
respectively). Likewise and in a complementary manner, lag phase
was increased for both complex I- and complex II-sustained
respiration (10.766.0% and 13.165.5%, respectively; Table 4)
and DYmax was only slight, yet significantly, decreased when
substrates for complex II were used (1.160.5% and 2.260.6% for
complex I and II, respectively).
Hepatic and renal mitochondrial fractions behaved similarly,
both having decreased DYmax with complex I substrates
(1.960.5% and 1.660.4%, respectively; Table 5). Slower state 3
respiration (6.663.8%) in hepatic fractions and kidney
(12.664.2%) with complex I substrates was also measured. Along
with a decreased state 3 respiration, liver mitochondria also
showed a longer phosphorylative lag phase (27.1611.6%). RCR
Table 3. Echocardiogram parameters in the sub-chronic protocol.
IVS (mm)
LPWT
(mm) LVDd (mm) LVDs (mm)
LV mass
(mg) LVEF (%) FS (mm) AT s/d (bpm)
Model Treatment Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE
Sub-Chronic Saline (n=4) 1.49 0.05 1.54 0.05 5.02 0.21 2.44 0.13 416.3 44.7 87.3 0.8 51.2 1.1 520.8 15.1
DOX (n=4) 1.50 0.03 1.55 0.02 5.00 0.22 2.45 0.16 411.5 23.3 87.0 1.2 51.2 1.3 538.3 16.0
Differences between treatment groups were evaluated by non-parametric Mann-Whitney test due to their lack of normality (see Material and Methods for detailed
information). IVS – interventricular septum; LPWT – left posterior wall thickness; LVDd – left ventricular diastolic dimension; LVDs – left ventricular systolic dimension;
LVEF – left ventricular ejection fraction; FS – fraction shortening; AT s/d – arterial tension systole/diastole.
doi:10.1371/journal.pone.0038867.t003
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group in liver and renal mitochondrial.
Aconitase Activity
Aconitase activity was measured in all mitochondrial fractions
as a marker of oxidative stress [24]. Alterations in aconitase
activity were tissue-specific and treatment-dependent. The only
tissue that showed a decreased enzyme activity in the acute model
was the kidney (27.866.7%) while the activity remained unaltered
in the heart and liver (0.3611.8% and 15612.3%, respectively;
Table 5). Cardiac mitochondrial aconitase in the chronic model
was decreased by 21.567.7% in the DOX-treated group while
activity in the two other organs were unaltered (12.9615.6% and
5.469.0% for liver and kidney, respectively).
Discussion
The present work demonstrates that DOX treatment induced
different responses depending on the schedule protocol used.
Transaminases and total serum protein levels suggest that the
acute treatment affects the liver. Minor cytoplasmic vacuolization
observed in histological and electron microscopy of thin slices from
hepatic tissue may also suggest metabolic alterations in hepato-
cytes, which are supported by decreased triglyceride levels, despite
no alterations in plasma cholesterol (Table 2). Moreover, the slight
increase of state 3 respiration in the presence of complex I-linked
substrates (Fig. 4), which are the most important in a cellular
context, and adoption of the condensed mitochondrial conforma-
tion as seen by electron microscopy (Fig. 3), support the idea that
hepatocyte metabolism and viability are affected after the acute
treatment. Nevertheless, it is however unclear at the moment if
alterations in lipid metabolism can contribute to worsen the
cardiovascular fitness in treated animals. However, hyperlipidemia
was clearly observable in the sub-chronic treatment and liver
histology showed slightly more vacuolization that in the acute
model (Table 2 and Fig. 2), suggesting that altered lipid
metabolism may be a secondary response to drug treatment.
It is intriguing that sub-chronically-treated animals showed only
increase in plasma lipids, while other parameters and markers
were consistently decreased even those which are usually increased
in chronic exposure to DOX [16,28,29] (Table 2). Nevertheless,
because no substantial alterations in histology and ultrastructure
analysis were also detected (Fig. 2 and 3), we believe that the
organism of treated animals reached a new adaptive steady-state
following sub-chronic DOX toxicity. Nevertheless, organ alter-
ations may probably exist undetected which may lead to a
disrupted response when subjected to metabolic or physiological
stress.
Another interesting difference between treatments relates to
heart mass which was the only organ in both models to show an
alteration in this parameter. However, it was surprising to observe
a difference only in the acute model since hypertrophy is usually
reported along with DOX-induced cardiotoxicity [1,2,30]. Also
surprising was the 7% decrease in heart mass after 24 h of
treatment (Table 1). One hypothesis relates to apoptotic and/or
necrotic events associated with DOX peak dosage in the plasma
[29] and often observed in cardiac cells exposed to DOX [31].
Nevertheless, a previous work showed that a single injection of
10 mg/Kg DOX caused primarily a decrease in heart mass
followed by a restoration to control values [32], which may explain
why no alterations were observed in the sub-chronic model.
However, sample size in the mentioned study was too small for a
good interpretation of results. Nevertheless the authors explained
the weight recovery as an increase in cytoplasm volume and
Figure 2. Histological analysis of organs collected from rats
treated with DOX. No notorious differences or hallmarks of DOX
toxicity were found in the different tissues in both protocols. Panels
represent HE photographs of random chosen tissues: hearts present
minor cytoplasmatic vacuolization (Panel B) and cytoplasmatic dilata-
tion (Panel D); liver usually show minor cytoplasmatic vacuolization
(Panel F and H); no changes in kidneys (Panel J and L). Organs were
fixed in Bouin’s solution, processed through standard histological
procedures and stained with HE (for more information, see Material and
Methods).
doi:10.1371/journal.pone.0038867.g002
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in our two models.
The loss of cardiac structure and deteriorated function usually
observed in long-term treatment with DOX [33,34] was not
present in our model, supporting the idea of unaltered organ
physiology. However, an interesting work performed on young
mice demonstrated that chronic DOX treatment did not result in
any sign of cardiomyopathy until animals were subject to a
stressful swimming protocol [11]. The dissimilarities between
studies, including our own, where no alterations in heart mass in
DOX-treated rats were detected and other reports where those
alterations were measured [8,11,35,36], may be explained by the
different rat strains used or by the fact that the alterations may
only be triggered in the presence of a physiological stress. In fact,
this idea is put in use in the clinical practice where general
diagnostic techniques for cardiac function, such as echocardio-
grams, are performed with increased workload and demands for
higher cardiac output increasing therefore the specificity of
screening and decreasing the number of false negatives [37,38].
In fact, the concept of normal organ physiology during resting
conditions but altered when submitted to a stressful event led us to
investigate mitochondrial function, since we can artificially
Figure 3. Cellular ultra-structure remains intact after acute or sub-chronic DOX treatment. No notorious differences or hallmarks of DOX
toxicity were found in the different tissues in both protocols. Panels represent electron microphotographs of randomly chosen tissues: hearts present
well-defined Z-bands and organized myofibrils (Panel C,D and L–O) and minor cytoplasmatic dilatation (Panel M and O); livers show cytoplasmatic
vacuolization (Panel E, G and S) and lipid-like droplets structures (Panel Q) and some mitochondria appear in the condensed conformation (Panel G);
renal mitochondria appear in an intermediated conformation between orthodox and condensed form (Panel X). Organs were fixed in 4%
gluteraldehyde and post-fixed in osmium (for more information, see Material and Methods).
doi:10.1371/journal.pone.0038867.g003
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e38867stimulate this model system, by creating a pseudo-metabolic stress
by the addition of ADP. Furthermore, alterations of cardiac
mitochondrial function were already described [37]. Once again, a
different response to DOX treatment was observed in the two
models. Mitochondrial alterations, as assessed by oxygen con-
sumption and transmembrane electric potential, were noticeable
in both treatment protocols but the degree of effect and their
targets were distinct. If one assumes that the extension of statistical
significance of the 7 distinct end-points regarding respiration/
transmembrane electric potential (Table 4, Fig. 4 and 5) can
indicate the extension of treatment damage to mitochondria (total
of 14 parameters for tissue specificity, 21 for respiratory complex
specificity and 42 for model specificity) we can make the following
assumptions: a) Mitochondrial dysfunction is clearly more present
in the sub-chronic model with 11/42 parameters altered in
comparison to 2/42 in the acute, b) Cardiac mitochondria in the
acute model are the less affected population with 0/14 altered
parameters while both hepatic and renal mitochondria have at
least one (1/14) altered parameter, c) Contrarily, heart mitochon-
dria is the most affected group in the sub-chronic model with 6/14
altered parameters compared to the liver (3/14) and kidney (2/14)
and d) DOX-treatment also leads to more alterations in complex-I
sustained respiration with 2/21 and 8/21 altered parameters in
acute and sub-chronic model, respectively, in comparison to
complex-II sustained respiration which had 0/21 and 4/21 altered
parameters in same treatment schedules, respectively. It seems
therefore plausible to consider that mitochondrial bioenergetic
dysfunction, together with harmful effects of DOX on energy
substrate channeling, synthesis and availability [2,39] may be prior
and thus responsible for altered cardiac metabolism and structure
remodeling.
Oxygen consumption and calcium-loading capacity were
previously reported to be accurate markers for DOX-induced
mitochondriopathy [13,26,29,36,39]. Although some argue about
the sensitivity of mitochondrial bioenergetics parameters [15],
state 3 respiration was a good indicator for mitochondrial
dysfunction in this study since it uncovered differences between
tissues and treatment protocols. Importantly, changes in this
parameter were detected before changes in organ structure or
function occurred.
DOX is known for its futile redox cycle on mitochondrial
complex I [40]. DOX enhances the production of ROS which is
closely related to mitochondrial toxicity and further damage to cell
tissue. In the present study, activity of the tricarboxylic acid cycle
enzyme aconitase, an indirect but specific marker of oxidative
Table 5. Effects of DOX on mitochondrial aconitase activity.
Model Treatment Heart Liver Kidney
Mean SE Mean SE Mean SE
%
Acute Saline (n=6) 100 13.1 100 12.5 100 12.7
DOX (n=6) 100.3 12.8 85.0 18.9 72.2** 9.0
Sub-Chronic Saline (n=5) 100 10.4 100 14.7 100 11.7
DOX (n=5) 78.5* 14.5 112.9 25.9 105.4 12.4
Differences between treatment groups means within the same model were
evaluated by matched pairs Student’s t test to exclude the variability related to
mitochondrial isolation (see Material and Methods for detailed information).
*p#0.05;
**p#0.01 vs saline group of the same model. SE – standard error.
doi:10.1371/journal.pone.0038867.t005
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PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e38867stress, was used. The profile of enzyme inhibition followed the
previous idea that DOX toxicity is treatment schedule and target-
specific; cardiac aconitase activity was decreased in the sub-
chronic model while it was unchanged in the acute (Table 5). The
results suggest increased cardiac mitochondrial oxidative stress in
the sub-chronic model but not in the acute; in this latter case,
only kidney mitochondria presented decreased aconitase activity.
This was rather surprising since we were expecting effects in both
models due to the fact that DOX accumulates rapidly in the
tissue and remains at high levels even after the treatment is ended
[41]. In fact, DOX-induced increase in oxidative stress is
exacerbated in long-term treatments since the primary damage
of reactive oxygen species (ROS) on mitochondrial DNA can lead
to a defective respiratory chain, increasing therefore the
productions of ROS. Nevertheless, we believe that oxidative
stress is indeed present in the acute model but perhaps
antioxidant enzymes were also up-regulated, as previously
described [42], although more work is needed in this regard.
Interestingly, most published works done by using animal models
and a single injection with higher DOX concentrations found
evidences of cardiomyopathy several days later [14,43,44,45].
Although this observation is not consistent with the well-known
late-onset DOX-induced cardiomyopathy, we believe that
previous studies combined with our present data suggest a
possible time window where strategies to counteract the drug
toxicity can be effectively applied.
To our knowledge this was the first time that a 7+1 week
treatment protocol was used in Wistar rats. Since different rat
strains differ in their metabolism and susceptibility to toxic agents
[46,47], data interpretation from the present work is not directly
comparable to previous data using other rat strains, including
Sprague-Dawley [8,15,26,35,36,48], which may present different
tolerance to DOX. Interestingly, the results from Sprague-Dawley
[6,9,27] and Wistar rats (our study) suggest that the former are
more susceptible to DOX cardiotoxicity. Although needed to be
confirmed by a new study, the differences between rat strains
corroborate the idea of polymorphism-driven susceptibility to
chemotherapy [49,50]. In fact, the same sub-chronic protocol in
Sprague-Dawley caused extensive ascites (Oliveira, personal
communication), a marker of heart failure, which was absent in
the present work.
Our data confirms once again the idea of a preferential toxicity
targeted to the heart although this was now clearly demonstrated
in a multi-organ experimental model. Moreover, mitochondrial
dysfunction is detected before detection of cardiomyopathy as
assessed by echocardiography, or morphological changes. Animals
appear to be mostly normal although presenting impaired cardiac
mitochondrial function, which may pre-dispose these organelles
for failure during stressful events. The results suggest that DOX
cardiotoxicity is better revealed when animals models or humans
are placed under stress, as referred in this study [11]. Stressful
events can include pregnancy, which has been described to present
a higher risk in survivors of childhood leukemia treated with DOX
[51].
In conclusion, our data confirms that mitochondrial dysfunction
is one major cause of DOX-selective cardiotoxicity and not a
consequence as sometimes is questioned [29,30]. The present work
is also the first to provide a three organ analysis of DOX toxicity
using two different experimental protocols in Wistar rats. DOX
did not cause substantial morphological or echocardiographic
alterations in the heart or any other organs analyzed, although
cardiac mitochondria showed alterations. Therefore, data con-
firms that mitochondrial alterations result from DOX treatment,
being more severe in the heart and which are dependent on the
treatment protocol. Thus, mitochondrial dysfunction is an early
marker of DOX toxicity, although it remains to be determined if
mitochondrial alterations in organs such as liver and kidney are a
direct effect of DOX on mitochondria or instead if they result from
secondary effects of DOX on other target tissues.
Supporting Information
Figure S1 PubMed results distribution of research
involving ‘‘doxorubicin’’ and ‘‘mitochondria’’ according
to tissue category. The Venn diagram presented in the figure
was elaborated after collecting data from the PubMed website
(assessment date February 27
th) using specific #keywords to obtain
the desired output. Briefly, papers in the database that included
works related to the #drug and #mitochondria were retrived,
restricting the output for research performed in the defined #tissue,
excluding #reviews and works performed in #humans as long as
they are not indexed with other animals. Therefore, the base of the
search string was as follow: (((#mitochondria AND #drug) AND
#tissue) NOT #reviews) NOT #humans Further explanation
about each of the keywords is given in supporting Table 1. The
authors recognize that the present search string is not flawless;
however, the idea is to give the reader an overview of report
rankings across the selected tissues. In fact, we acknowledge the
fact that, for example, the keyword #humans will not include
recent reports since they are yet to be indexed to Medline.
(TIF)
Table S1 Description of keywords used in PubMed
search for construction of Venn diagram of Fig.5, as well
as the number of results retrieved with for each
corresponding keyword.
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Figure 5. Respiratory Control Ratio (RCR) and ADP phosphor-
ylated per consumed oxygen ratio (ADP/O). A – heart; B – liver; C
– kidney. Bars represent means of treatment groups (saline in white
bars; DOX in black bars) with SE. Differences between treatment
groups means within the same model were evaluated by matched pairs
Student’s t test to exclude the variability related to mitochondrial
isolation and electrode calibration but when assumptions were rejected
the non-parametric Wilcoxon matched pairs test was applied (see
Material and Methods for detailed information). *, p#0.05 vs saline
group of the same model. n=10, 9 and 10 (acute model – heart, liver
and kidney, respectively) or n=12, 11 and 12 (sub-chronic model –
heart, liver and kidney, respectively). GM - glutamate/malate; SUC -
succinate.
doi:10.1371/journal.pone.0038867.g005
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